Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $365000.0.

  • Gyre Therapeutics' Cash from Financing Activities rose 1265.43% to $365000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 5279.03%. This contributed to the annual value of $2.1 million for FY2024, which is 1592.0% down from last year.
  • As of Q3 2025, Gyre Therapeutics' Cash from Financing Activities stood at $365000.0, which was up 1265.43% from $22.4 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Cash from Financing Activities registered a high of $49.5 million during Q1 2021, and its lowest value of -$45.0 million during Q3 2022.
  • In the last 5 years, Gyre Therapeutics' Cash from Financing Activities had a median value of $240000.0 in 2024 and averaged $2.1 million.
  • In the last 5 years, Gyre Therapeutics' Cash from Financing Activities plummeted by 4861250.0% in 2023 and then soared by 1422756.41% in 2025.
  • Over the past 5 years, Gyre Therapeutics' Cash from Financing Activities (Quarter) stood at $98000.0 in 2021, then tumbled by 46045.92% to -$45.0 million in 2022, then skyrocketed by 133.85% to $15.2 million in 2023, then tumbled by 93.67% to $964000.0 in 2024, then tumbled by 62.14% to $365000.0 in 2025.
  • Its Cash from Financing Activities stands at $365000.0 for Q3 2025, versus $22.4 million for Q2 2025 and $1.3 million for Q1 2025.